Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.

Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation - 1 Apr 2018

Rubin Raymond A, Russo Mark W, Brown Kimberly A, Fontana Robert J, Levitsky Josh, Vargas Hugo, Yoshida Eric M, Brown Robert S

Abstract excerpt

OBJECTIVES: Our objective was to determine the safety, efficacy, and pharmacokinetics of telaprevir plus pegylated interferon alfa 2a and ribavirin for chronic, posttransplant genotype 1 hepatitis C virus infection. MATERIALS AND METHODS: A prospective, single-arm, multicenter, open-label, phase 2b study was conducted at 22 North American sites to assess the safety, efficacy, and pharmacokinetics of pegylated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Calcineurin Inhibitors
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Interactions

Share to Liver Transplantation

Share to North America

Share to Oligopeptides

Share to Polyethylene Glycols

Share to Sustained Virologic Response

Source

Identifiers

PMID: 27855589
DOI: 10.6002/ect.2016.0251

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Twice-Daily Telaprevir for Posttransplant Genotype 1 Hepatitis C Virus: A Prospective Safety, Efficacy, and Pharmacokinetics Study.PMID 27855589Read ↗

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C.Semantic proximity Read ↗

Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C.Semantic proximity Read ↗

Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection.Semantic proximity Read ↗

Combination therapy with telaprevir for chronic hepatitis C virus genotype 1 infection in patients with HIV: a randomized trial.Semantic proximity Read ↗

Telaprevir for the treatment of chronic hepatitis C infection.Semantic proximity Read ↗

A US multicenter study of hepatitis C treatment of liver transplant recipients with protease-inhibitor triple therapy.Semantic proximity Read ↗

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.Semantic proximity Read ↗

Multicenter experience using telaprevir or boceprevir with peginterferon and ribavirin to treat hepatitis C genotype 1 after liver transplantation.Semantic proximity Read ↗

The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.Semantic proximity Read ↗

Telaprevir: a new hope in the treatment of chronic hepatitis C?Semantic proximity Read ↗

Telaprevir: a hepatitis C NS3/4A protease inhibitor.Semantic proximity Read ↗

Telaprevir: a review of its use in the management of genotype 1 chronic hepatitis C.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.